The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer

Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), a coregulator of the estrogen receptors (ERs) alpha and beta, is a potential proto-oncogene in hormone dependent gynecological malignancies. To better understand the role of PELP1 in epithelial ovarian cancer (EOC), the protein expression...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2013-03, Vol.13 (1), p.115-115, Article 115
Main Authors: Aust, Stefanie, Horak, Peter, Pils, Dietmar, Pils, Sophie, Grimm, Christoph, Horvat, Reinhard, Tong, Dan, Schmid, Bernd, Speiser, Paul, Reinthaller, Alexander, Polterauer, Stephan
Format: Article
Language:English
Subjects:
Adult
Aged
Biomarkers, Tumor - metabolism
Breast cancer
Cancer
Cancer patients
Carcinoma - metabolism
Care and treatment
Chemotherapy
Co-Repressor Proteins - metabolism
Development and progression
Endometrial cancer
Estrogen
Estrogen Receptor alpha - metabolism
Estrogen Receptor beta - metabolism
Estrogens
Female
Glutamate
Hormones
Humans
Immunohistochemistry
Microarray Analysis
Middle Aged
Ovarian cancer
Ovarian Neoplasms - metabolism
Patient outcomes
Phenols
Prognosis
Proline
Proteins
Receptors
Regression Analysis
Survival Analysis
Transcription Factors - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), a coregulator of the estrogen receptors (ERs) alpha and beta, is a potential proto-oncogene in hormone dependent gynecological malignancies. To better understand the role of PELP1 in epithelial ovarian cancer (EOC), the protein expression and prognostic significance of PELP1 was evaluated together with ERalpha and ERbeta in EOC tissues. The expression of PELP1, ERalpha, and ERbeta was characterized in tumor tissues of 63 EOC patients. The prognostic value was calculated performing log-rank tests and multivariate Cox-Regression analysis. In a second step, validation analysis in an independent set of 86 serous EOC patients was performed. Nuclear PELP1 expression was present in 76.2% of the samples. Prevalence of PELP1 expression in mucinous tumors was significantly lower (37.5%) compared to serous (85.7%) and endometrioid tumors (86.7%). A significant association between PELP1 expression and nuclear ERbeta staining was found (p=0.01). Positive PELP1 expression was associated with better disease-free survival (DFS) (p=0.004) and overall survival (OS) (p=0.04). The combined expression of ERbeta+/PELP1+ revealed an independent association with better DFS (HR 0.3 [0.1-0.7], p=0.004) and OS (HR 0.3 [0.1-0.7], p=0.005). In the validation set, the combined expression of ERbeta+/PELP1+ was not associated with DFS (HR 0.7 [0.4-1.3], p=0.3) and OS (HR 0.7 [0.3-1.4], p=0.3). Positive immunohistochemical staining for the ER coregulator PELP1, alone and in combination with ERbeta, might be of prognostic relevance in EOC.
ISSN:1471-2407
1471-2407
DOI:10.1186/1471-2407-13-115